Company intelligence / Profile preview

Toyobo

Osaka, Osaka Prefecture, Japantoyobo-global.com ↗

Ownership: Private
Employees: ~9976
Development stage: Commercial

Overview

Toyobo’s life science division supplies a broad range of commercialized products including diagnostic enzymes and reagents for molecular biology and clinical testing. Their PCR test reagents saw high demand during the COVID‑19 pandemic. The company also produces hollow fiber membranes used in dialysis devices and has launched new in vitro diagnostic products targeting infectious diseases[2][6]. No therapeutics or drugs are reported to be in preclinical or clinical development.

Therapeutic areas: OtherNephrologyInfectious Diseases
Modalities: EnzymeAntibodyMagnetic beadDiagnostic reagent
Industry: Molecular Diagnostics

Drug pipeline

1 asset

SARS-CoV-2 Detection Kit

Commercial

Indications: COVID-19

Partnerships

DMC Biotechnologies Inc. (joint development agreement on sustainable compounds)[9]

Beyond the preview

Go deeper on Toyobo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Toyobo.

Explore the full profile